Skip to main content
padlock icon - secure page this page is secure

Free Content Editorial [Hot topic: Receptor-Targeted Cancer Therapy (Guest Editor: Li-Chun Sun)]

Download Article:
(PDF 16.7 kb)
Conventional radiotherapy and chemotherapy have been applied to treatments after surgery or advanced/metastatic cancers. However, the applications have been limited, partly due to non-specificity that results in toxic side effects and to the eventual multi-drug resistance (MDR) that results from prolonged treatments. Considerable interest has been placed on receptor-targeted cancer therapy following the development of monoclonal antibody (mAb) technology by Kohler and Milstein in 1975. Certain receptors, such as somatostatin (SST) receptors (SSTRs) and gastrin releasing peptide (GRP) receptors, are found aberrantly expressed in much higher concentrations in many cancer cells than they are in normal cells. Peptides and mAbs used as drugdelivery systems have been broadly applied in receptor-targeted tumor imaging and radiotherapy/chemotherapy. During recent years, receptor-targeted nanotechnology has been developed as well. Generally, receptor-targeted therapeutics could increase efficacy and specificity, decrease toxic side effects and MDR. A classical example of increasing therapeutic specificity is that the SSTR2-specific AN-238, a conjugate of an octapeptide SST analog and 2-pyrrolino-DOX, displays potent indirect antitumor activity against human SSTR-negative non-SCLC NCI-H157 xenografts by directly targeting SSTR-positive tumor blood vessels of the host mice. However, these approaches display their own advantages and disadvantages, although great progress has been made. Peptides have some extra advantages. For instance, they are easy to synthesize and optimize and can be quickly investigated for their therapeutic potential since many peptides are relatively small molecules with very few amino acids. Many of these peptides undergo rapid internalization, quick circulatory clearance and good tumor tissue-penetrating ability. But peptides have a short half-life and lack both selectivity and high affinity compared to mAbs. mAbs have limited tumor penetration due to their large size and antigen heterogeneity to cancer cells, but have the advantages of high affinity, specificity and stability. Furthermore, antibodies need much more time to be taken up by tumors. Fab fragments of antibodies are quickly taken up by tumors, but rapid and high renal accumulation with low tumor-uptake rates limits their applications. Nanoparticles can be easily taken up by cancer cells and also by normal cells. In this thematic issue, we collect eight papers from different fields including receptor-targeted applications of nanoparticles, peptides and antibodies. Our attempt is to show the most current progression in these fields.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.

    The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.

    The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more